Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 2, 2003, Pages 191-196

  Ohwada, Jun ^a   Tsukazaki, Masao ^a   Hayase, Tadakatsu ^a   Oikawa, Nobuhiro ^a   Isshiki, Yoshiaki ^a   Fukuda, Hiroshi ^a   Mizuguchi, Eisaku ^a   Sakaitani, Masahiro ^a   Shiratori, Yasuhiko ^a   Yamazaki, Toshikazu ^a   Ichihara, Shigeyasu ^a   Umeda, Isao ^a   Shimma, Nobuo ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PRODRUG; RO 0098557; TRIAZOLE; ANTIFUNGAL AGENT; SOLVENT; TRIAZOLE DERIVATIVE; WATER;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; DEGRADATION; DRUG STABILITY; DRUG SYNTHESIS; ENZYME ACTIVATION; LUNG ASPERGILLOSIS; ANIMAL; BIOTRANSFORMATION; CHEMICAL STRUCTURE; CONFORMATION; DRUG DESIGN; HALF LIFE TIME; HAPLORHINI; HUMAN; IN VITRO STUDY; MICROBIOLOGY; PH; PHYSICAL CHEMISTRY; RAT; SOLUBILITY; SYNTHESIS;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; BIOTRANSFORMATION; CANDIDIASIS; CHEMISTRY, PHYSICAL; DRUG DESIGN; HALF-LIFE; HAPLORHINI; HUMANS; HYDROGEN-ION CONCENTRATION; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PRODRUGS; RATS; SOLUBILITY; SOLVENTS; TRIAZOLES; WATER;

EID: 17644440661     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00892-2     Document Type: Article

References (17)

1. (a) Maesaki S., Kohno S. Saishin Igaku. 47:1992;277
2. (b) Ohno, R.; Mizoguchi, H.; Kume, H. Nikkei Medical Aug. 10, 1993, 40.
3. (c) Saxena S., Khan J.A., Ghosh P.C. J. Antimicrob. Chemother. 42:1998;635
4. (d) Petit C., Cheron M., Joly V., Rodrigues J.M., Bolard J., Gaboriau F. J. Antimicrob. Chemother. 42:1998;779.
5. (a) Fung-Tomc J.C., White T.C., Minassian B., Huczko E., Bonner D.P. Diagn. Microbiol. Infect. Dis. 35:1999;163.
6. (b) Kitazaki T., Ichikawa T., Tasaka A., Hosono H., Matsushita Y., Hayashi R., Okonogi K., Itoh K. Chem. Pharm. Bull. 48:2000;1935.
7. (c) Van Cutsem J. Mycoses. 32:1989;14.
8. (d) Nakamura, H.; Yamada, A.; Ohki, H.; Maki, K.; Kitano, Y.; Takasugi, H.; Tanaka, H. Abstracts, The 17th Symposium on Medicinal Chemistry, 6th Annual Meeting of Division of Medicinal Chemistry, Abstract No. 1P-09, Nov. 19-21, 1997; The Pharmaceutical Society of Japan: Tsukuba, Japan.
9. (a) Ohwada, J.; Murasaki, C.; Yamazaki, T.; Ichihara, S.; Umeda, I.; Shimma, N. Bioorg. Med. Chem. Lett. 12, 2775.
10. (b) Ichikawa T., Kitazaki T., Matsushita Y., Yamada M., Hayashi R., Yamaguchi M., Kiyota Y., Okonogi K., Itoh K. Chem. Pharm. Bull. 49:2001;1102.
11. (c) Ueda, Y; Matiskella, J. D.; Golik, J; Hudyma, T. W.; Chen, C. WO 01/52852, 2001.
12. Ohwada, J.; Tsukazaki, M.; Hayase, T.; Oikawa, N.; Isshiki, Y.; Umeda, I.; Yamazaki, T.; Ichihara, S.; Shimma, N. Abstracts, The 21st Symposium on Medicinal Chemistry, 10th Annual Meeting of Division of Medicinal Chemistry, Abstract No. 1P-06, Nov. 28-30, 2001; The Pharmaceutical Society of Japan: Kyoto, Japan.
13. Bogardus J.B., Higuchi T. J. Pharm. Sci. 71:1982;729.
14. Among several amino acid esters, sarcosine ester was chosen from its physicochemical and safety property.
15. Acetaldehyde is most likely safe at the clinical dose of the prodrug.
16. 5 S·Cl.HCl: Cl, 8.98. Found: Cl, 9.27.
17. Compound 22 as well as 1 showed no toxicity at the clinical dose in rat and monkey, respectively.